The long-term objectives of the research described in this project are to understand mechanisms by which the widely used analgesic/antipyretic, acetaminophen, interacts with other drugs, and to characterize at the molecular level enzymes involved in the interactions. This is important to avoid life-threatening hepatic necrosis initiated by N-acetyl-p- benzoquinone imine, a reactive metabolite of acetaminophen formed by several cytochrome P450s that metabolize many other drugs. Results of previous studies implicate CYP2E1 and CYP2A6 as major catalysts in the oxidation of acetaminophen to its toxic quinoneimine and non-toxic catechol metabolites, respectively, and inhibition/induction of CYP2E1 by other drugs, such as isoniazid and ethanol, can increase or decrease risk of hepatotoxicity caused by acetaminophen depending on the time of ingestion relative to consequences of ligand regulation of CYP2E1. We propose to continue our studies of P450s responsible for the oxidation of acetaminophen in the next grant period. The first Specific Aim of this proposal is to construct active site models of CYP2E1 and CYP2A6 that are consistent with the different product selectivities of these two P450 isoforms for the quinoneimine and catechol metabolites of acetaminophen. A multi-tiered approach will be used that incorporate the results of NMR paramagnetic relaxation studies, homology and CoMFA modelling, mutagenesis experiments, and studies with mechanism- based inactivators. The second Specific Aim is to assess the roles of CYP2E1, CYP3A4 and dysregulation of hepatocyte mitochondrial glutathione status in the market toxicity of acetaminophen in individuals who chronically consume ethanol. This interaction has been suggested to be the leading cause of acute liver failure in the U.S. The interactions is multifaceted and the proposed studies continue an evaluation of this interaction initiated during the last grant period. A rat model will be used to investigate the separate effects of changes in acetaminophen reactive metabolite formation clearance and hepatocyte mitochondrial GSH status on hepatocellular damage. A series of studies will be conducted in human volunteers to determine the contribution of CYP2E1 and CYP3A P450 isoforms to acetaminophen reactive metabolite formation in vivo at acetaminophen doses relevant to the interaction and the effects that moderate drinking of alcoholic beverages and starvation have on this clinical syndrome.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM032165-19
Application #
6481914
Study Section
Project Start
2001-08-01
Project End
2002-07-31
Budget Start
Budget End
Support Year
19
Fiscal Year
2001
Total Cost
$254,104
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wong, Timothy; Wang, Zhican; Chapron, Brian D et al. (2018) Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metab Dispos 46:367-379
Shirasaka, Y; Chaudhry, A S; McDonald, M et al. (2016) Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 16:375-87
Manoj, Kelath Murali; Parashar, Abhinav; Gade, Sudeep K et al. (2016) Functioning of Microsomal Cytochrome P450s: Murburn Concept Explains the Metabolism of Xenobiotics in Hepatocytes. Front Pharmacol 7:161
Stamper, Brendan D; Garcia, Michael L; Nguyen, Duy Q et al. (2015) p53 Contributes to Differentiating Gene Expression Following Exposure to Acetaminophen and Its Less Hepatotoxic Regioisomer Both In Vitro and In Vivo. Gene Regul Syst Bio 9:1-14
McDonald, Matthew G; Au, Nicholas T; Rettie, Allan E (2015) P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms. Drug Metab Dispos 43:1661-9
Chaudhry, Amarjit S; Prasad, Bhagwat; Shirasaka, Yoshiyuki et al. (2015) The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug Metab Dispos 43:1226-35
Liu, Li; Collier, Ann C; Link, Jeanne M et al. (2015) Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. Drug Metab Dispos 43:1795-804
Ho, Han Kiat; Chan, James Chun Yip; Hardy, Klarissa D et al. (2015) Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metab Rev 47:21-8
Chapron, Brian; Risler, Linda; Phillips, Brian et al. (2015) Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes. J Pharm Pharm Sci 18:101-11
Hsiao, Peng; Unadkat, Jashvant D (2014) Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies. Mol Pharm 11:436-44

Showing the most recent 10 out of 361 publications